The Kechuang 50 index opened slightly lower in the morning on April 12. The index began to decline after briefly turning red at the beginning of the trading day. It showed a trend of shock and decline in the early trading day. It once fell about 1.9% in the afternoon, followed by a sharp rebound with the main board stock index, adjusted after turning red, rose in the late trading day, and finally closed up slightly. At the close, the Kechuang 50 index was at 994.44 points, up 0.57%, and the index amplitude was 2.51%.
From the disk perspective, the performance of Kechuang 50 index is weaker than that of Shanghai stock index and gem index; Most of the stocks on the science and technology innovation board followed the rebound trend, and the overall increase was small. Only 15 stocks rose by more than 5%.
In terms of segments, biopharmaceutical stocks showed differentiation, and the other segments showed a slight general rise.
Weijie Chuangxin and Haichuang pharmaceutical were listed on the science and Innovation Board of Shanghai Stock Exchange on April 12, and the number of listed enterprises on the science and innovation board has increased to 409.
The securities code of Weijie Chuangxin is 688153, and the issue price is 66.60 yuan / share. Weijie Chuangxin is an integrated circuit design enterprise focusing on the R & D, design and sales of RF front-end chips. It mainly provides customers with RF power amplifier module products, as well as RF switch chips, Wi Fi RF front-end modules and other integrated circuit products. It is widely used in various terminal products with wireless communication functions such as smart phones, tablets, wireless routers and smart wearable devices. As of the closing, Weijie Chuangxin fell 36.04% compared with the issue price, the turnover rate was 46.85%, and the turnover was about 666 million yuan.
The securities code of Haichuang pharmaceutical is 688302, and the issue price is 42.92 yuan / share. Haichuang pharmaceutical Haichuang pharmaceutical is an international innovative drug enterprise based on deuterated technology, protac targeted protein degradation and other technical platforms, aiming at developing best in class and first in class drugs with major clinical needs. As of the closing, Haichuang pharmaceutical fell 29.87% compared with the issue price, the turnover rate was 64.49%, and the turnover was about 483 million yuan.
According to the statistics of Xinhua Finance and economics, as of the closing, excluding the two new shares on the first day of listing, the average increase of the remaining 407 stocks on the science and Innovation Board was 1.19%, the average turnover rate was 2.01%, and the total turnover was 28.87 billion yuan, with an average amplitude of 4.70%.
In terms of individual stock performance, dingyang technology rose 11.68%, the highest increase; Excluding the two new shares on the first day of listing, Shan Dong Kexing Bioproducts Co.Ltd(688136) fell by 6.39%, ranking the first.
In terms of turnover, Zhejiang Orient Gene Biotech Co.Ltd(688298) turnover is billion yuan, ranking first; The turnover was million yuan, ranking last.
In terms of turnover rate, regardless of the two new shares on the first day of listing, the turnover rate is%, ranking first; The turnover rate was%, ranking last.
